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Long-term survival rates, such as 5-, 10- or 20-years survival rates
are essential outcome measures of cancer, and they are now
routinely reported by many cancer registries from different parts of
the world. Unfortunately, traditional estimates of long-term
survival, which pertain to cohorts of patients diagnosed many
years ago, may be seriously outdated in case of recent improve-
ment in survival. For example, in the 1999 report from the EURO-
CARE project, a collaborative effort of the population based
European cancer registries to provide standardized data on cancer
patient survival, 5-year survival rates were reported for patients
diagnosed in 1985–1989 and followed with respect to survival
until the end of 1994 (Berrino et al, 1999). Similarly, a recent
analysis from the United States provided 5-, 10- and 15-year
survival rates for patients diagnosed in 1974–1991 with a follow-
up through 1992 (Wingo et al, 1998). 
Recently, a new method of survival analysis, denoted period
analysis, has been developed (Brenner and Gefeller, 1996), which
has been shown to provide more up-to-date estimates of long-term
survival rates (Brenner and Gefeller, 1997), but, with few excep-
tions (Brenner et al, 1998, 1999), the method has rarely been
applied by cancer registries so far. We applied period analysis to
data from the nationwide Finnish cancer registry to provide up-to-
date estimates of long-term survival rates achieved by the end 
of the 20th century. In this paper, we present period estimates of 
5-, 10-, 15- and 20-year relative survival rates pertaining to the
1995–1997 period (the most recent period for which complete data
were available at the time of analysis) for the 16 most common
forms of cancer, and we compare them with the corresponding
survival estimates that might have been obtained from the same
database by traditional methods of survival analysis. 
MATERIALS AND METHODS 
Data base 
Our analysis is based on data from the nationwide Finnish 
Cancer Registry (population base: about 5.1 million people) 
which are among the highest quality data of any population-based
cancer registry in the world. Virtually complete population-
based cancer registration has been accomplished since 1953
(Teppo et al, 1994). Notification of cancer cases to the registry is
mandatory by law, and it comes from many different sources,
including hospitals, physicians working outside hospitals, dentists,
and pathological and cytological laboratories. Copies are also
obtained of all death certificates where cancer is mentioned. 
Mortality follow-up is extremely efficient in Finland due to the
existence of personal identification numbers (Dickman et al,
1999). Using these numbers as the key, the cancer registry files are
matched annually with the annual list of deaths. Matching with the
central population register (a register of all people currently alive
and living in Finland) is performed as an additional check on the
vital status of patients. By the time of this analysis, follow-up with
respect to vital status had been completed until the end of 1997. 
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http://www.bjcancer.comThe current analysis includes patients diagnosed with one of the
16 most common forms of cancer (excluding non-melanoma skin
cancer) in Finland between 1975 and 1997. Patients whose cancer
was registered by death certificate only (about 2% of registered
cases) or whose month of death was unknown (1.9%) were
excluded from the analysis. 
Methods of analysis 
Throughout this paper, we present relative rather than absolute
survival rates (Ederer et al, 1961). Relative survival rates (RSR)
are the preferred measures of survival reported by cancer
registries, because they are unaffected by deaths from causes other
than the primary cancer of interest. The RSR, which represents the
survival rate in the hypothetical situation where the cancer in ques-
tion is the only possible cause of death, is defined as the absolute
survival rate among cancer patients divided by the expected
survival rate of a comparable group from the general population.
We estimated the expected survival rates from nationwide popula-
tion life tables stratified by age, sex and calendar time according to
the approach commonly known as the Ederer II method (with
minor adaptations for the application of period analysis) (Ederer
and Heise, 1959). 
For each cancer site, the period estimates of 5-, 10-, 15- and 20-
year RSR were obtained for the 1995–1997 period, the most recent
3-year period for which both registration of new cases and
mortality follow up was complete at the time of analysis. Details
of period analysis have been reported elsewhere (Brenner and
Gefeller 1996, 1997). Briefly, the period estimates are obtained by
left truncation of observations at the beginning of some recent
period of interest (here: beginning of 1995) in addition to right
censoring at its end (here: end of 1997). This ensures that period
estimates, in contrast to traditional survival estimates, exclusively
reflect survival experience during some recent time period (here:
1995–1997). 
The most recent estimates of RSR obtained by traditional
methods of survival analysis are reported for comparison.
Traditional methods include ‘cohort analysis’ which focuses on
cohorts of patients who have been under observation for the entire
follow-up period of interest, and ‘complete analyses’ which addi-
tionally includes more recently diagnosed patients who have not
completed the entire follow-up period of interest at the closing
date of follow-up (here: end of 1997), but who are censored at that
point of time. Survival figures reported by cancer registries so far
have been derived either by pure forms of cohort or complete
analysis, or by mixed forms of them (in that only patients who had
been under observation for some minimum follow-up period were
included). 
Derivation of cohort, complete and period survival estimates
presented in this paper and their differences are illustrated for 5-
year survival rates in Figure 1. The most recent cohort estimate of
5-year survival pertains to patients diagnosed in 1990–1992 all of
whom have completed 5-year follow-up by the end of 1997 (solid
frame). In the derivation of the most recent period estimate,
different parts of the survival function are obtained from the
survival experience in 1995–1997 of patients diagnosed in
different years (dashed frame). The complete estimates reflect the
entire survival experience in 1990–1997 of patients diagnosed 
in 1990–1997, which includes the survival experience on which
the cohort and the period estimates are based as overlapping 
sub-components. 
For all methods, 95% confidence intervals of 5-year RSR,
derived by Greenwood’s method (Greenwood, 1926) are provided
along with the point estimates. 
RESULTS 
Table 1 provides an overview on the types of cancer and the
numbers of patients diagnosed in 1975–1997 who are included in
this analysis. The most common forms of cancer were breast and
lung cancer with an average of more than 2000 incident cases per
year, followed by cancer of the prostate, stomach and colon.
Analyses for the less common forms of cancer included in this
paper, cancer of the esophagus and cervical cancer, are still based
on an average number of about 200 cases per year. Table 1 also
provides trends in 5-year relative survival rates (derived by cohort
analysis) for patients diagnosed in various time intervals between
1975–1977 and 1990–1992. As expected, tremendous differences
in prognosis between cancer sites were observed for patients diag-
nosed in each of the four time intervals, with the highest 5-year
RSR for cancers of the breast and the corpus uteri and for
melanoma, and very low 5-year RSR for cancers of the pancreas,
oesophagus and lung. Unfortunately, the latter hardly changed
over time. By contrast, there was major improvement in prognosis
over time for most other forms of cancer. Improvements were most
pronounced for cancers of the stomach, colon, breast, kidney,
bladder, the nervous system and for melanoma and leukaemia.
These trends underline the importance of approaches that provide
the most up-to-date estimates of long term survival rates. 
The most up-to-date estimates of 5-year RSR and their 95%
confidence intervals derived by the different methods of survival
analysis are presented in Table 2. 
Whereas 5-year RSR estimates from cohort, complete and
period analysis were rather similar for cancers of the oesophagus
(7.5–7.7%), stomach (24.8–26.4%), pancreas (2.4–2.6%), lung
(9.6–9.8%), nervous system (55.8–56.9%) and for melanoma
(81.3–82.4%), there were major differences for other cancer sites
(with the highest estimates obtained by period analysis and the
lowest estimates obtained by cohort analysis). Differences were
most salient for cancer of the uterine cervix (55.4–67.8%) and the
prostate (63.5–72.6%), but major differences were also seen for
cancer of the colon (52.7–57.6%), rectum (48.0–54.8%), ovaries
(45.7–51.2%) and the bladder (68.7–75.3%) and for leukaemia
(41.9–47.3%). Although 95% confidence intervals are somewhat
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Figure 1 Survival experience included in the most up-to-date estimates of
5-year survival rates obtained by cohort analysis (solid frame), complete
analysis (entire area), and period analysis (dashed frame). The figures 1–5
within the cells indicate the years of follow-up since diagnosis the particular
cell defined by calendar years of diagnosis and follow-up is contributing to wider for estimates from cohort and period analyses than for esti-
mates from complete analysis, the lower bounds of 95% confi-
dence intervals of period estimates often exceed or are very close
to the point estimates from complete analysis for those cancers
with major differences in estimates from the three types of
analysis. 
The differences between the three types of estimates are gener-
ally more pronounced for 10-year RSR (see Table 3). For example,
period estimates, different from the traditional estimates, disclose
that 10-year RSR have now come close to (or even exceed) 80%
for cancer of the corpus uteri and melanoma, 75% for breast
cancer, 70% for bladder cancer, 65% for cancer of the cervix uteri,
and 55% for cancer of the colon and prostate. 
Still stronger differences between the different types of estimates
are seen for 15- and 20-year RSR. In particular, 20-year period esti-
mates of RSR are much higher than traditional 20-year estimates of
RSR for all common cancer sites except those few cancers for
which there has been virtually no improvement in prognosis over
time and whose long-term prognosis has remained discouragingly
poor, namely cancer of the pancreas and lung. For these cancers,
the period estimates of 20-year RSR (1.9% and 3.7%, respec-
tively) are very similar to the corresponding estimates obtained by
traditional survival estimates. By contrast, period analysis
suggests that 20-year RSR has now come close to (or even
exceeds) 75% for endometrial cancer and melanoma, 60% for
breast cancer and cervical cancer, 55% for colon cancer and
bladder cancer, and 40–50% for cancer of the rectum, the ovaries,
kidneys and nervous system. These estimates typically exceed the
corresponding complete and cohort estimates by 5 to 15 per cent
units and 10 to 20 per cent units, respectively. 
A more comprehensive illustration of the major differences in
the most up-to-date survival estimates obtained by the different
methods of analysis is given by the 20-year relative survival
curves, which are shown for breast cancer, the most common form
of cancer among women, in Figure 2. For example, according to
cohort and complete analysis, cumulative tumour associated
mortality of 20% (corresponding to an RSR of 80%) is reached as
early as about 2.5 and 4.5 years after diagnosis, respectively,
compared to about 6.5 years according to period analysis.
Cumulative tumour-associated mortality of 40% (corresponding to
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Table 1 Number of patients included in this analysis and trends in 5-year relative survival rates (RSR, in %)
by type of cancer. Database: Finnish Cancer Registry, 1975–1997 
5-year RSR of patients diagnosed in 
Cancer site Sex n 1975–77 1980–82 1985–87 1990–92 
Oesophagus f+m 4645 4.8 6.9 8.3 7.5 
Stomach f+m 24 901 12.9 17.9 19.7 24.8 
Colon f+m 20 483 38.6 47.3 47.4 52.7 
Rectum f+m 14 857 40.1 42.0 47.8 48.0 
Pancreas f+m 13 070 1.4 1.5 2.8 2.4 
Lung f+m 47 767 8.9 9.9 11.6 9.7 
Breast f 51 529 67.4 73.4 76.8 81.6 
Cervix uteri f 4033 60.4 57.5 56.2 55.5 
Corpus uteri f 11 617 74.9 75.9 75.1 80.3 
Ovary f 10 798 36.0 44.8 42.9 45.7 
Prostate m 31 355 52.4 55.2 60.5 63.5 
Kidney f+m 11 609 35.5 40.4 46.9 54.1 
Bladder f+m 13 916 52.1 62.3 64.2 68.7 
Melanoma f+m 9515 66.9 75.3 79.9 81.3 
Nervous system f+m 12 500 41.0 55.0 59.7 55.8 
Leukaemia f+m 8347 24.2 28.2 35.9 41.9 
Table 2 Most up-to-date 5-year relative survival estimates (95% confidence intervals) for the most
common forms of cancer according to cohort analysis, complete analysis and period analysis.
Database: Finnish Cancer Registry, 1990–1997 
Cancer site Cohort analysis Complete analysis Period analysis 
Oesophagus 7.5 (5.1–9.9) 7.7 (5.8–9.6) 7.7 (5.2–10.2) 
Stomach 24.8 (23.1–26.6) 25.1 (23.8–26.5) 26.4 (24.5–28.3) 
Colon 52.7 (50.5–54.9) 54.7 (53.1–56.3) 57.6 (55.4–59.7) 
Rectum 48.0 (45.4–50.6) 51.2 (49.2–53.2) 54.8 (52.1–57.4) 
Pancreas 2.4 (1.6–3.1) 2.6 (2.0–3.3) 2.6 (1.8–3.5) 
Lung 9.7 (8.9–10.5) 9.8 (9.2–10.5) 9.6 (8.7–10.4) 
Breast 81.6 (80.5–82.7) 82.5 (81.7–83.4) 83.4 (82.4–84.4) 
Cervix uteri 55.5 (50.0–61.0) 60.8 (56.9–64.7) 67.8 (62.7–72.8) 
Corpus uteri 80.3 (77.8–82.8) 81.3 (79.6–83.1) 82.4 (80.0–84.7) 
Ovary 45.7 (43.1–48.4) 48.7 (46.7–50.6) 51.2 (48.6–53.9) 
Prostate 63.5 (61.3–65.6) 68.9 (67.2–70.5) 72.6 (70.6–74.6) 
Kidney 54.1 (51.5–56.8) 55.5 (53.6–57.5) 58.3 (55.6–60.9) 
Bladder 68.7 (65.9–71.5) 71.7 (69.6–73.7) 75.3 (72.6–78.1) 
Melanoma 81.3 (78.6–84.0) 81.5 (79.5–83.6) 82.4 (79.8–85.1) 
Nervous system 55.8 (53.5–58.2) 56.8 (55.1–58.4) 56.9 (54.6–59.2) 
Leukaemia 41.9 (38.6–45.1) 44.2 (41.8–46.6) 47.3 (43.9–50.6) an RSR of 60%) is reached about 7.5 years and 12.5 years after
diagnosis according to cohort and complete analysis, respectively,
whereas it remains below that level for more than 20 years
according to period analysis. 
DISCUSSION 
Monitoring of cancer survival rates is among the most important
tasks of population-based cancer registries. To be useful for both
clinical practice and public health purposes, estimates of survival
rates should be as up-to-date as possible. It has previously been
shown that changes in survival rates are more timely detected by
period analysis, a recently introduced new method of survival
analysis, than by traditional methods of survival analysis (Brenner
and Gefeller, 1996, 1997). Our application of period analysis to the
most recent survival data in the Finnish cancer registry confirms that
the method of analysis matters indeed when one attempts to derive
the most up-to-date long term survival estimates. For all but few
forms of cancer, whose prognosis remained virtually unchanged
over time, period analysis yielded substantially higher long-term
survival estimates than the traditional methods of analysis. 
The differences in survival estimates obtained by the different
types of analysis increase with increasing length of follow-up, and
they are particularly strong for 10-, 15- and 20-year survival rates.
The reason for that is that traditional long-term survival estimates,
in contrast to period estimates, are strongly influenced by survival
experience in the early years following diagnosis (when most
cancer deaths occur) of patients diagnosed many years ago. They
may thus be seriously outdated in case of recent major progress in
survival, e.g. by advances in cancer therapy. 
While the period approach has only recently been introduced in
survival analysis, it is well established in other fields of science.
For example, a widely used integrative (inverse) measure of total
mortality over various ages is the life expectancy. The by far most
commonly used measures to describe life expectancy achieved by
the end of the 20th century are estimates from period life tables for
some recent year (e.g. the year 1999), which reflect the mortality
experience of people born at various parts of the century (who
contribute mortality rates at various ages in 1999). One could also
use a cohort approach to describe the life expectancy of the most
recent cohort of people who has virtually died out by the end of the
century (i.e., people born a lifespan ago), but these estimates
would be dramatically lower as they would reflect mortality rates
partly dating back a very long time ago. 
Although period estimates of survival are more up-to-date than
traditional estimates of survival, they still may lag behind the
survival experience of newly diagnosed patients in the case of
ongoing improvement in survival. To evaluate this issue further,
we systematically compared the long-term survival rates actually
observed for cohorts of Finnish cancer patients diagnosed in
various time intervals between 1963 and 1992 with the most up-to-
date estimates of long-term survival rates that might have been
obtained from the Finnish Cancer Registry data at the time of diag-
nosis of these patients. This analysis gave a very consistent picture
(data not shown): except for the few cancers, whose prognosis
virtually remained unchanged over time, all types of survival
analysis yielded ‘conservative’ estimates, i.e., estimates that were
lower than those later observed for newly diagnosed patients, but
in all cases, this discrepancy was much smaller for period analysis
than for complete analysis and for cohort analysis. 
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Table 3 Most up-to-date 10-, 15- and 20-year relative survival estimates for the most common forms of cancer according to
cohort analysis, complete analysis and period analysis. Database: Finnish Cancer Registry, 1985–1997, 1980–1997 and
1975–1997, respectively 
10-year RSR 15-year RSR 20-year RSR 
Cancer site Cohort Complete Period Cohort Complete Period Cohort Complete Period 
Oesophagus 7.6 7.6 7.3 5.1 6.8 7.5 3.8 5.9 8.9 
Stomach 17.7 21.3 24.3 15.0 18.5 23.3 8.9 14.2 21.0 
Colon 43.1 48.9 55.6 42.0 46.5 54.2 32.4 43.5 53.5 
Rectum 40.5 42.5 48.1 34.5 39.7 48.2 32.0 37.5 47.9 
Pancreas 1.8 1.9 2.2 1.0 1.6 1.8 1.3 1.5 1.9 
Lung 7.7 7.1 6.6 4.5 5.0 4.9 3.3 3.7 3.7 
Breast 65.8 70.0 73.5 51.9 59.7 66.6 40.8 51.7 61.8 
Cervix uteri 49.9 51.9 64.1 45.3 47.9 60.5 45.7 45.1 60.6 
Corpus uteri 70.8 75.7 80.4 69.7 71.4 77.4 64.7 67.0 73.9 
Ovary 38.6 42.2 46.0 36.7 37.9 42.0 27.7 35.4 41.9 
Prostate 41.6 47.2 53.4 31.6 35.1 41.2 20.6 24.6 30.6 
Kidney 38.9 45.0 50.3 25.5 35.9 46.1 22.3 32.3 42.5 
Bladder 54.4 61.3 68.4 46.8 53.0 63.3 27.3 42.3 56.5 
Melanoma 77.4 78.0 79.3 65.9 72.6 78.3 58.6 69.1 76.1 
Nervous system 55.3 52.0 51.3 42.7 46.6 48.6 31.6 42.6 46.4 
Leukaemia 25.3 29.7 35.3 14.5 21.1 28.5 10.3 16.0 23.7 
Figure 2 Most up-to-date 20-year relative survival curves for breast cancer
according to cohort analysis, complete analysis and period analysis.
Database: Finnish Cancer Registry, 1975–1997
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)We therefore believe that the period estimates of long-term
survival provided in this paper give a better picture of chances of
long-term survival achieved by the end of the 20th century than
previously available estimates that were based on traditional
methods of survival analysis. According to our analysis, long-term
survival rates are substantially higher than previously available
figures for most forms of cancer indeed. For example, in the 1999
report of the EUROCARE project, cohort estimates of 5-year RSR
were reported for patients diagnosed in 1985–1989 (Berrino et al,
1999). For the Finnish cancer patients, these cohort estimates were
quite similar as, and in some cases (stomach cancer, ovarian
cancer, kidney cancer and leukaemia) even substantially lower
than the cohort estimates for the 1990–1992 cohorts presented in
this paper. For all cancers except for those with virtually no
improvement over time (cancer of the oesophagus, pancreas and
lung and melanoma of the skin), however, the cohort estimates
published in the 1999 EUROCARE report are substantially lower
than the period estimates reported in this paper. Another recent
comprehensive analysis of cancer patient survival in Finland
reported also 10-year RSR (Dickman et al, 1999). In this analysis,
10-year RSR were derived for patients diagnosed in 1985–1994
and followed with respect to mortality until the end of 1995. This
approach comes very close to a ‘pure form’ of complete analysis.
Despite some variation due to the different years included in the
analysis, results are quite close to the estimates from complete
analysis reported in this paper, but they are substantially lower
than estimates from period analysis for some forms of cancer with
recent major improvement in prognosis (such as colorectal cancer,
cancer of the cervix uteri and ovarian cancer). 
For most forms of cancer, survival rates of cancer patients in
Finland were somewhat higher than average survival rates from
the European countries included in the recent EUROCARE report
(Berrino et al, 1999). Nevertheless, there was a large variation
between countries, and substantially higher rates were reported for
some cancers from other countries. Likewise, the most recently
reported survival estimates for white cancer patients in the United
States (Greenlee et al, 2000) are often substantially higher than the
survival rates reported from Finland so far (and even higher than
the period estimates reported in this paper). These survival rates
were also derived by traditional methods of survival analysis, and
we therefore suspect that still substantially higher survival esti-
mates would be obtained for these populations if period analysis
was applied. We suggest to apply period analysis along with tradi-
tional techniques of survival analysis in comparative analyses of
survival rates across registries in the future in order to obtain the
most up-to-date possible picture of variation in survival rates
across populations. 
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